Roche to integrate Methotrexate test from ARK Diagnostics into therapeutic drug monitoring menu for clinical chemistry analyzers
In a channel partnership approach, ARK will distribute test kits to Roche customers for use on cobas c 501/502 analyzers
Roche (SIX: RO, ROG; OTCQX: RHHBY) and ARK Diagnostics announced today a distribution agreement that will enable laboratories to integrate ARK’s Methotrexate test into the Roche therapeutic drug monitoring (TDM) menu for its cobas c 501 and cobas c 502 clinical chemistry analyzers. The TDM Methotrexate cobas c test kits are used to provide information to help healthcare professionals manage patients on cancer drug therapy.
“Roche is committed to providing a comprehensive menu of assays to support the varying needs of our customers. The addition of ARK’s Methotrexate test to the Roche test menu will provide access for our customers to a specialized test for cancer drug monitoring with proven quality and performance,” said Randy Pritchard, senior vice president of Roche Professional Diagnostics. “This partnership demonstrates our commitment to finding innovative ways to offer a more comprehensive TDM portfolio.”
“Using the ‘partner channel’ approach to integrate our Methotrexate test into the menu on Roche analyzers will enable many more clinical laboratories to expand the testing services they can offer to physicians for therapeutic drug monitoring,” added Robert O’Malley, vice president of marketing, sales and service of ARK . “We look forward to further collaboration with Roche in the field of drug monitoring tests.”
ARK will begin distributing the kits to Roche customers in October 2014.
About ARK Diagnostics
Headquartered in Fremont, California, and founded in 2003, ARK Diagnostics Inc. designs, manufactures, and distributes in vitro diagnostic products. ARK’s proprietary assays accurately measure drug levels in biological fluids. Clinicians use these measurements to guide dosing decisions for safe, effective, and personalized drug therapy. By optimizing drug levels, clinicians improve outcomes, reduce toxicity, and lower healthcare costs. ARK is dedicated to improving the quality of patient health through better therapeutic drug management. For more information, please visit www.ark-tdm.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.